Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hye Kyoung Hong is active.

Publication


Featured researches published by Hye Kyoung Hong.


Journal of Neuroinflammation | 2014

Neonatal systemic inflammation in rats alters retinal vessel development and simulates pathologic features of retinopathy of prematurity

Hye Kyoung Hong; Hyun Ju Lee; Jung Hwa Ko; Ji Hyun Park; Ji Yeon Park; Chang Won Choi; Chang-Hwan Yoon; Seong Joon Ahn; Kyu Hyung Park; Se Joon Woo; Joo Youn Oh

BackgroundAlteration of retinal angiogenesis during development leads to retinopathy of prematurity (ROP) in preterm infants, which is a leading cause of visual impairment in children. A number of clinical studies have reported higher rates of ROP in infants who had perinatal infections or inflammation, suggesting that exposure of the developing retina to inflammation may disturb retinal vessel development. Thus, we investigated the effects of systemic inflammation on retinal vessel development and retinal inflammation in neonatal rats.MethodsTo induce systemic inflammation, we intraperitoneally injected 100 μl lipopolysaccharide (LPS, 0.25 mg/ml) or the same volume of normal saline in rat pups on postnatal days 1, 3, and 5. The retinas were extracted on postnatal days 7 and 14, and subjected to assays for retinal vessels, inflammatory cells and molecules, and apoptosis.ResultsWe found that intraperitoneal injection of LPS impaired retinal vessel development by decreasing vessel extension, reducing capillary density, and inducing localized overgrowth of abnormal retinal vessels and dilated peripheral vascular ridge, all of which are characteristic findings of ROP. Also, a large number of CD11c+ inflammatory cells and astrocytes were localized in the lesion of abnormal vessels. Further analysis revealed that the number of major histocompatibility complex (MHC) class IIloCD68loCD11bloCD11chi cells in the retina was higher in LPS-treated rats compared to controls. Similarly, the levels of TNF-α, IL-1β, and IL-12a were increased in LPS-treated retina. Also, apoptosis was increased in the inner retinal layer where retinal vessels are located.ConclusionsOur data demonstrate that systemic LPS-induced inflammation elicits retinal inflammation and impairs retinal angiogenesis in neonatal rats, implicating perinatal inflammation in the pathogenesis of ROP.


Investigative Ophthalmology & Visual Science | 2016

Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model

Sang Jun Park; Yewon Choi; Young Mi Na; Hye Kyoung Hong; Ji Yeon Park; Kyu Hyung Park; Jae Yong Chung; Se Joon Woo

PURPOSEnWe determined the intraocular pharmacokinetic properties of intravitreally injected aflibercept (Eylea) in a rabbit model.nnnMETHODSnAflibercept was injected intravitreally in 21 eyes from New Zealand White rabbits. The eyes were enucleated 1, 24, 48, 120, 216, 360, and 720 hours (1, 2, 5, 9, 15, and 30 days, respectively) after injection and immediately frozen at -80°C. The concentrations of aflibercept in the vitreous, aqueous humor, and retina/choroid were determined by performing an indirect enzyme-linked immunosorbent assay, and analyzed to understand the pharmacokinetic properties of the drug.nnnRESULTSnThe maximum concentration of aflibercept was observed 1, 48 (2 days), and 24 (1 day) hours after intravitreal administration in the vitreous, aqueous humor, and retina/choroid, respectively. The one-compartment model was selected as the final model for all three ocular tissues. In the vitreous, aqueous humor, and retina/choroid, the estimated half-lives of aflibercept were 94.1, 48.0, and 58.2 hours, and the estimated mean residence times (MRTs) were 135.8, 69.2, and 84.0 hours, respectively. The area under curve from time 0 to the end point (AUClast) was 135,810.6 hours × μg/mL for the vitreous, 13,889.7 hours × μg/mL for the aqueous humor, and 2453.1 hours × μg/g for the retina/choroid.nnnCONCLUSIONSnIn rabbits, the vitreous half-life of aflibercept is 94.1 hours (3.92 days). This is shorter than that of bevacizumab (6.99 days), and longer than that of ranibizumab (2.51 days) and VEGF-Trap (3.63 days).


Eye | 2015

Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model

Sang Jun Park; Jaeseong Oh; Kim Yk; Park Jh; Park Jy; Hye Kyoung Hong; Kyo Hoon Park; Lee Je; Kim Hm; Jae-Yong Chung; Se Joon Woo

PurposeTo determine intraocular pharmacokinetic properties of intravitreally injected vascular endothelial growth factor (VEGF)-Trap in a rabbit model.MethodsVEGF-Trap was intravitreally injected in 18 rabbit eyes. Eyes were enucleated 1u2009h and 1, 2, 5, 14, and 30 days after injections and immediately frozen at −80u2009°C. Concentration of VEGF-Trap in vitreous, aqueous humor, and retina/choroid was determined using an indirect enzyme-linked immunosorbent assay and analyzed to obtain pharmacokinetic properties.ResultsMaximum concentration of VEGF-Trap was achieved at 1u2009h in all three tissues. A one-compartment model of distribution was selected as the final model for all tissues studied. Estimated half-life of VEGF-Trap in vitreous, aqueous humor, and retinal/choroid was 87.1, 36.8, and 35.0u2009h, respectively, and estimated mean residence time was 125.7, 53.1, and 50.5u2009h, respectively. Area under the curve from time 0 to the end point was 10009.8, 3945.1, and 1189.3, respectively. Total exposure of the aqueous humor and retina/choroid to VEGF-Trap was 39.4% and 11.9% of vitreous exposure, respectively.ConclusionThe vitreous half-life of VEGF-Trap is 3.63 days. This is shorter than that of bevacizumab (6.99 days) and longer than that of ranibizumab (2.51 days), as shown in studies using the same experimental settings. The concentration of VEGF-Trap peaked at 1u2009h after injections in all eye tissues studied.


Investigative Ophthalmology & Visual Science | 2014

Identification of Vinculin as a Potential Plasma Marker for Age-Related Macular Degeneration

Hye-Jung Kim; Se Joon Woo; Eui Jin Suh; Jeeyun Ahn; Ji Hyun Park; Hye Kyoung Hong; Ji Eun Lee; Seong Joon Ahn; Duck Jin Hwang; Ki Woong Kim; Kyu Hyung Park; Cheolju Lee

PURPOSEnTo identify plasma protein biomarkers for age-related macular degeneration (AMD) using a large-scale quantitative proteomic discovery procedure.nnnMETHODSnPlasma proteomes from 20 exudative AMD patients and 20 healthy control patients were comparatively profiled by four-dimensional liquid chromatography-tandem mass spectrometry (LC-MS/MS). Proteins existing at statistically different levels were validated by enzyme-linked immunosorbent assay (ELISA) and Western blotting in 233 case-controlled samples. Newly discovered plasma biomarkers were further confirmed using in vivo and in vitro experiments.nnnRESULTSnOut of 320 proteins identified, vinculin, protein S100A9, triosephosphate isomerase, protein S100A8, protein Z-dependent protease inhibitor, C-X-C motif chemokine 7, and tenascin X showed significantly differential expression in AMD patient plasma compared to control plasma. Among these, the area under the curve (AUC) for vinculin was 0.871 for discriminating between exudative AMD and controls (n = 201) and 0.879 for discriminating between AMD and controls (n = 233). A proteogenomic combination model using vinculin and two known risk genotypes in ARMS2 and CFH genes additionally provided excellent discrimination of AMD from controls (AUC = 0.916). The plasma level of vinculin was not associated with any confounding clinical variables, such as age, smoking, and other comorbidities. Additionally, vinculin was strongly expressed in retinal pigment epithelial cells of human eyes, and its expression was elevated when exposed to oxidative stress in vitro.nnnCONCLUSIONSnVinculin was identified as a potential plasma biomarker for AMD. The early detection of AMD using novel plasma biomarkers with genetic modeling may enable timely treatment and vision preservation in the elderly.


Investigative Ophthalmology & Visual Science | 2016

Imaging laser-induced choroidal neovascularization in the rodent retina using optical coherence tomography angiography

Jang Ryul Park; WooJhon Choi; Hye Kyoung Hong; Yongjoo Kim; Sang Joon Park; Yoonha Hwang; Pilhan Kim; Se Joon Woo; Kyu Hyung Park; Wang-Yuhl Oh

PURPOSEnThe purpose of this study was to evaluate the performance of optical coherence tomography angiography (OCTA) in visualizing laser-induced choroidal neovascularization (CNV) in the rodent retina.nnnMETHODSnChoroidal neovascularization was induced via laser photocoagulation in 2 male Brown Norway rats and 2 male C57BL/6 mice. For qualitative comparison, the animals were imaged in vivo with OCTA, indocyanine green angiography (ICGA), and fluorescein angiography (FA), and ex vivo with immunofluorescence confocal microscopy, 14 days post laser photocoagulation without anti-vascular endothelial growth factor (anti-VEGF) intervention. For longitudinal quantitative analysis, CNV was induced in 6 additional male C57BL/6 mice. Three mice intravitreally received an anti-VEGF agent and the remaining 3 mice phosphate buffered saline (PBS) vehicle 7 days post laser photocoagulation. These animals were imaged using OCTA 6, 14, and 21 days post laser photocoagulation. The area and volume of the laser-induced CNV lesions were measured longitudinally.nnnRESULTSnIn both mice and rats, OCTA qualitatively showed high correlation with FA, ICGA, and immunofluorescence imaging. Unlike FA and ICGA, which does not show the microvasculature due to dye leakage, OCTA visualized the CNV microvasculature with resolution and contrast comparable to immunofluorescence images. Longitudinal imaging enabled normalization of the CNV area and volume, reducing inherent variation in the CNV size. By using only 3 mice in each group, statistically significant differences (P < 0.01) in the CNV area and volume could be demonstrated.nnnCONCLUSIONSnOptical coherence tomography angiography enables noninvasive visualization of the laser-induced CNV microvasculature in the rodent retina with high resolution and tissue-lumen contrast, providing quantifiable in vivo measurements for longitudinal analysis.


Scientific Reports | 2016

Proteomics-based identification and validation of novel plasma biomarkers phospholipid transfer protein and mannan-binding lectin serine protease-1 in age-related macular degeneration

Hye-Jung Kim; Seong Joon Ahn; Se Joon Woo; Hye Kyoung Hong; Eui Jin Suh; Jeeyun Ahn; Ji Hyun Park; Na-Kyung Ryoo; Ji Eun Lee; Ki Woong Kim; Kyu Hyung Park; Cheolju Lee

Age-related macular degeneration (AMD) is a major cause of severe, progressive visual loss among the elderly. There are currently no established serological markers for the diagnosis of AMD. In this study, we carried out a large-scale quantitative proteomics analysis to identify plasma proteins that could serve as potential AMD biomarkers. We found that the plasma levels of phospholipid transfer protein (PLTP) and mannan-binding lectin serine protease (MASP)-1 were increased in AMD patients relative to controls. The receiver operating characteristic curve based on data from an independent set of AMD patients and healthy controls had an area under the curve of 0.936 for PLTP and 0.716 for MASP-1, revealing excellent discrimination between the two groups. A proteogenomic combination model that incorporated PLTP and MASP-1 along with two known risk genotypes of age-related maculopathy susceptibility 2 and complement factor H genes further enhanced discriminatory power. Additionally, PLTP and MASP-1 mRNA and protein expression levels were upregulated in retinal pigment epithelial cells upon exposure to oxidative stress in vitro. These results indicate that PLTP and MASP-1 can serve as plasma biomarkers for the early diagnosis and treatment of AMD, which is critical for preventing AMD-related blindness.


Molecular Pharmaceutics | 2016

Anti-VEGF PolysiRNA Polyplex for the Treatment of Choroidal Neovascularization

Jihwang Lee; Na-Kyung Ryoo; Hyounkoo Han; Hye Kyoung Hong; Ji Yeon Park; Sang Jun Park; Yong-Kyu Kim; Changbeom Sim; Kwangmeyung Kim; Se Joon Woo; Kyu Hyung Park; Hyuncheol Kim

Choroidal neovascularization (CNV) is a major cause of severe vision loss in patients with age-related macular degeneration (AMD). Present ocular siRNA delivery technology is limited due to poor delivery through the retina to the choroid, where CNV originates. Our goal was to develop an optimized nanosized polyRNAi-based therapeutic delivery system to the subretinal space. We developed it by siRNA multimerization (polysiRNA) followed by coating with branched polyethylenimine and hyaluronic acid, and then evaluated its efficacy in vitro and in vivo. The polysiRNA polyplex showed a narrow size distribution (260.7 ± 43.27 nm) and negative charge (-4.98 ± 0.47 mV) owing to the hyaluronic acid outer layer. In vitro uptake of the polysiRNA polyplex by human ARPE cells was discovered, and the direct inhibition of VEGF mRNA translation was confirmed in B16F10 cells. The intravitreally administered polysiRNA polyplex overcame both the vitreous and retina barriers in vivo and reached the subretinal space efficiently. Intravitreal injection of the polysiRNA polyplex was not toxic to the retina in histopathology. Furthermore, intravitreal injections of the polysiRNA polyplex at both 1 and 7 days after laser photocoagulation inhibited laser-induced choroidal neovascularization, compared to that of the control (p < 0.05). These results suggest that anti-VEGF polysiRNA polyplexes show great potential in delivering multimeric RNAi-based therapeutics to treat retinal or choroidal disorders.


Investigative Ophthalmology & Visual Science | 2017

Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs

Kwangsic Joo; Sang Jun Park; Yewon Choi; Jung Eun Lee; Young Mi Na; Hye Kyoung Hong; Kyu Hyung Park; Ho Min Kim; Jae-Yong Chung; Se Joon Woo

PurposenTo identify the role of the fragment crystallizable (Fc) region in determining intraocular protein drug pharmacokinetics.nnnMethodsnWe generated a new VEGF-Trap lacking the Fc region (FcfVEGF-Trap, MWt = 100 kDa) by replacing the Fc region of native VEGF-Trap (MWt = 145 kDa) with a dimerized coiled-coil domain. Forty-two rabbits were injected intravitreally with VEGF-Trap or FcfVEGF-Trap (n = 21 each) in one of the eyes, harvested at six time points (1 hour and 1, 2, 4, 14, and 30 days after injections). VEGF-Trap and FcfVEGF-Trap concentrations in the vitreous, aqueous humor, and retina/choroid were measured, and drug pharmacokinetic properties were analyzed.nnnResultsnIn all three ocular compartments, the maximal concentrations for both FcfVEGF-Trap and VEGF-Trap were observed at 1 hour after injection. Half-lives of FcfVEGF-Trap in the vitreous and retina/choroid (145.02 and 102.12 hours, respectively) were 1.39 and 2.30 times longer than those of VEGF-Trap (103.99 and 44.42 hours, respectively). Total exposure of the aqueous humor and retina/choroid to FcfVEGF-Trap was 13.2% and 39% of the vitreous exposure, respectively, whereas VEGF-Trap concentrations were 25.2% and 26.2%, indicating that FcfVEGF-Trap shows a preference for posterior distribution and elimination.nnnConclusionsnFcfVEGF-Trap, despite its lower molecular weight, showed longer half-lives in vitreous and retina/choroid than VEGF-Trap did, suggesting that Fc receptors in ocular tissues contribute to anti-VEGF drug elimination. Truncation or mutation of the Fc region can prolong the intraocular residence time of VEGF-Trap and possibly reduce the number of VEGF-Trap injections required in clinical practice.


Journal of Visualized Experiments | 2016

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.

Seong Joon Ahn; Hye Kyoung Hong; Young Mi Na; Sang Jun Park; Jeeyun Ahn; Jaeseong Oh; Jae Yong Chung; Kyu Hyung Park; Se Joon Woo

The intraocular route of drug administration enables the delivery of high concentrations of therapeutic drugs, while minimizing their systemic absorption. Several drugs are administered into the anterior chamber or vitreous, and the intraocular injection has been effective in curing various intraocular diseases. Rabbit eyes have been widely used for ophthalmic research, as the animal is easy to handle and economical compared to other mammals, and the size of a rabbit eye is similar to that of a human eye. Using a 30 G needle, drugs can be injected into the intracameral and intravitreal spaces of rabbit eyes. The eyeballs are then frozen until analysis, and can be divided into the aqueous humor, vitreous, and retina/choroid. The vitreous and retina/choroid samples can be homogenized and solubilized before analysis. Then, immunoassays can be performed to measure the concentrations of intraocular drugs in each compartment. Appropriate pharmacokinetic models can be used to calculate several parameters, such as the half-life and maximum concentration of the drug. Rabbit eyes can be a good model for pharmacokinetic studies of intraocular drugs.


Investigative Ophthalmology & Visual Science | 2018

Oxygen-Induced Retinopathy and Choroidopathy: In Vivo Longitudinal Observation of Vascular Changes Using OCTA

Yongjoo Kim; Hye Kyoung Hong; Jang Ryul Park; WooJhon Choi; Se Joon Woo; Kyu Hyung Park; Wang-Yuhl Oh

PurposenThe purpose of this study was to assess the retinal and choroidal vasculatures of an oxygen-induced retinopathy (OIR) rat model using optical coherence tomography angiography (OCTA) as well as to verify the performance of OCTA for visualizing in vivo vascular alterations, longitudinally and quantitatively.nnnMethodsnTo induce OIR, Sprague Dawley rat pups were incubated in an 80% oxygen chamber from postnatal day 1 (P1) to P11 and returned to room air. OCTA imaging was performed in six eyes at P15, P18, P21, and P24. All eyes were imaged with ex vivo retinal flat mount immunofluorescence microscopy for comparison with OCTA. The areas of the neovascular tufts, retinal vessel tortuosities and diameters, and vessel densities of different retinal and choroidal layers were quantified.nnnResultsnThe neovascular tufts were observed in two OIR eyes. The tuft areas decreased spontaneously from P18 to P24. The increase in arterial tortuosity and venous dilation were observed in the OIR eyes at P15 and P18. The retardation of vascular developments was observed in the deep vascular plexus and the choroidal layer in the OIR group while the superficial vascular plexus did not show developmental delay.nnnConclusionsnThis study demonstrates an application of OCTA for quantitative and longitudinal studies on in vivo vascular alterations, including neovascular tufts, increase in arterial tortuosity, venous dilation, and developmental delay in the OIR rat model.

Collaboration


Dive into the Hye Kyoung Hong's collaboration.

Top Co-Authors

Avatar

Kyu Hyung Park

Seoul National University Bundang Hospital

View shared research outputs
Top Co-Authors

Avatar

Se Joon Woo

Seoul National University Bundang Hospital

View shared research outputs
Top Co-Authors

Avatar

Ji Hyun Park

Seoul National University Bundang Hospital

View shared research outputs
Top Co-Authors

Avatar

Sang Jun Park

Seoul National University Bundang Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ji Yeon Park

Seoul National University Bundang Hospital

View shared research outputs
Top Co-Authors

Avatar

Na-Kyung Ryoo

Seoul National University Bundang Hospital

View shared research outputs
Top Co-Authors

Avatar

Young Mi Na

Seoul National University Bundang Hospital

View shared research outputs
Top Co-Authors

Avatar

Cheolju Lee

Korea Institute of Science and Technology

View shared research outputs
Top Co-Authors

Avatar

Hye-Jung Kim

Korea Institute of Science and Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge